Weaver IC, Diorio J, Seckl JR, Szyf M, Meaney MJ (2004)
Therefore, it cannot be fully excluded that some of the transcriptional, metabolic, and anti-fibrotic changes observed in adipose tissue may represent secondary adaptations to reduced fat mass rather than exclusively direct pharmacological effects

Potential considerations include: Theoretical concern about promoting angiogenesis in existing tumors (not demonstrated but mechanistically plausible) Possible interactions with dopaminergic medications Limited human safety data due to absence of completed clinical trials GHK-Cu Side Effects# GHK-Cu has an established safety profile, particularly for topical use: Topical formulations are generally well-tolerated with low irritation potential Allergic reactions are rare but possible, particularly in individuals with copper sensitivity Injection site reactions (redness, swelling) can occur with subcutaneous administration No significant systemic side effects reported at standard research doses The extensive commercial use of GHK-Cu in cosmetic products provides a broader real-world safety dataset compared to BPC-157

Current clinical guidelines do not recommend GLP-1 agonists as first-line weight loss therapy for Type 1 diabetes, though emerging research suggests potential benefits under strict medical supervision
Furthermore, we used MRPRESSO (via the MRPRESSO R package, version 1.0) to detect and correct for outlier SNPs that might distort the causal estimates